

PROVIDER Update



CONTRACTUAL | AUGUST 27, 2025 | UPDATE 25-844 | 5 PAGES

Prior Authorization Requirement Changes, Effective July 1, 2025

Stay informed on new codes now in place

The following update includes prior authorization (PA) requirement coding changes. These apply to services, procedures and outpatient pharmaceuticals (submitted under the medical benefit) for Medicare fee-for-service FFS physicians and other providers.

How to access prior authorization requirements

Access the Medicare Prior Authorization requirements via either option below:

- Go to the Provider Library at providerlibrary.healthnetcalifornia.com > *Medicare Advantage* > *Prior Authorization Requirements* (on the left-hand side).
- Go to <https://bit.ly/HN-Prior-Auth> and select the *Medicare - California* Prior Authorization List.

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on Health Net's provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com, by telephone or through the Health Net provider portal as listed in the right-hand column. Behavioral health providers can call 844-966-0298.

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Behavioral Health Providers

LINES OF BUSINESS:

- Wellcare By Health Net
 - Medicare Advantage (HMO)

PROVIDER SERVICES

provider_services@healthnet.com

**Medicare (individual & employer group)
(Wellcare By Health Net) – 800-929-9224**

Medicare Supplement – 800-641-7761

**Behavioral Health providers –
844-966-0298**

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

CPT and HCPCS code changes, effective July 1, 2025

The below procedures, services and outpatient pharmaceuticals require PA per new CPT and HCPCS codes issued by the Centers for Medicare & Medicaid Services (CMS).

CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Code	Description	Category
0552U	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophoctoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder.	Genetic testing
0553U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophoctoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested.	Genetic testing
0552U	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophoctoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder.	Genetic testing
0553U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophoctoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested.	Genetic testing
0554U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophoctoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested.	Genetic testing
0555U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophoctoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested.	Genetic testing
0560U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	Genetic testing

Code	Description	Category
0561U	Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood, subsequent assessment with comparison to initial assessment to evaluate for MRD.	Genetic testing
0562U	Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as presence of actionable variants.	Genetic testing
0565U	Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6626 epigenetic alterations, cell-free DNA, plasma, algorithm reported as cancer signal detected or not detected.	Genetic testing
0566U	Oncology (lung), qPCR-based analysis of 13 differentially methylated regions (CCDC181, HOXA7, LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3, TBR1_2, TRAP1, VWC2, ZNF781), pleural fluid, algorithm reported as a qualitative result.	Genetic testing
0567U	Rare diseases (constitutional/heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants.	Genetic testing
0568U	Neurology (dementia), beta amyloid (AB40, AB42, AB42/40 ratio), tau-protein phosphorylated at residue (e.g., pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology.	Genetic testing
0569U	Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (> 20000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate.	Genetic testing
0571U	Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants.	Genetic testing
C9175	Injection, treosulfan, 50 mg.	Outpatient Pharmaceuticals (Part B medications)
C9174	Injection, datopotamab deruxtecan-dlnk, 1 mg.	Outpatient Pharmaceuticals (Part B medications)
J9174	Injection, docetaxel (Beizray®), 1 mg.	Outpatient Pharmaceuticals (Part B medications)
J2313	Injection, naloxone hydrochloride (Zimhi®), 0.01 mg.	Outpatient Pharmaceuticals (Part B medications)

Code	Description	Category
J1326	Injection, zolbetuximab-clzb, 2 mg.	Outpatient Pharmaceuticals (Part B medications)
J3391	Injection, atidarsagene autotemcel, per treatment.	Outpatient Pharmaceuticals (Part B medications)
J7172	Injection, marstacimab-hncq, 0.5 mg.	Outpatient Pharmaceuticals (Part B medications)
J7356	Injection, foscarbidopa. 0.25 mg/foslevodopa, 5 mg.	Outpatient Pharmaceuticals (Part B medications)
J9275	Injection, cosibelimab-ipdl, 2 mg.	Outpatient Pharmaceuticals (Part B medications)
J9276	Injection, zanidatamab-hrii, 2 mg.	Outpatient Pharmaceuticals (Part B medications)
J9289	Injection, nivolumab, 2 mg and hyaluronidase-nvhy.	Outpatient Pharmaceuticals (Part B medications)
J9341	Injection, thiotepa (Tepylute®), 1 mg.	Outpatient Pharmaceuticals (Part B medications)
J9342	Injection, thiotepa, not otherwise specified, 1 mg.	Outpatient Pharmaceuticals (Part B medications)
J9382	Injection, zenocutuzumab-zbco, 1 mg.	Outpatient Pharmaceuticals (Part B medications)
Q2058	Obecabtagene autoleucel, 10 up to 400 million CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per infusion.	Outpatient Pharmaceuticals (Part B medications)
Q4368	AmchoThick™, per square centimeter.	Wound therapy
Q4369	AmnioPlast 3, per square centimeter.	Wound therapy
Q4370	AeroGuard, per square centimeter.	Wound therapy
Q4371	NeoGuard, per square centimeter.	Wound therapy
Q4372	AmchoPlast™ EXCEL, per square centimeter.	Wound therapy
Q4373	Membrane Wrap-Lite, per square centimeter.	Wound therapy
Q4375	duoGRAFT AC™, per square centimeter.	Wound therapy
Q4376	Duograft AA™, per square centimeter.	Wound therapy
Q4377	triGRAFT FT™, per square centimeter.	Wound therapy
Q4378	Renew FT Matrix, per square centimeter.	Wound therapy
Q4379	AmnioDefend FT Matrix, per square centimeter.	Wound therapy
Q4380	AdvoGraft One, per square centimeter.	Wound therapy
Q4381	Matrix HD® allograft dermis, per square centimeter.	Wound therapy
Q4382	AdvoGraft Dual, per square centimeter.	Wound therapy
Q5098	Injection, ustekinumab-srlf (Imuldosa®), biosimilar, 1 mg.	Outpatient Pharmaceuticals (Part B medications)
Q5099	Injection, ustekinumab-stba (Steqeyma®), biosimilar, 1 mg.	Outpatient Pharmaceuticals (Part B medications)
Q5100	Injection, ustekinumab-kfce (Yesintek™), biosimilar, 1 mg.	Outpatient Pharmaceuticals (Part B medications)

Code	Description	Category
Q5153	Injection, aflibercept-yszy (Opviz™), biosimilar, 1 mg.	Outpatient Pharmaceuticals (Part B medications)